Mr. Stephen Mulvany:

This is the rebate that is due from the pharmaceutical manufacturers, in this case between those who are members of IPHA, the pharmaceutical association, under the IPHA agreement that commenced on 1 August 2016. We, the Department and the Department of Public Expenditure Reform have had a series of rolling three or four year agreements with the pharmaceutical suppliers who are members of IPHA. The latest agreement commenced on 1 August 2016. It provided for additional rebates, effectively additional price discounts.